

Robin Kate Kelley

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3345705/publications.pdf>

Version: 2024-02-01

56
papers

12,935
citations

126708

33
h-index

161609

54
g-index

59
all docs

59
docs citations

59
times ranked

9999
citing authors

#	ARTICLE	IF	CITATIONS
1	Futibatinib, an Irreversible FGFR1-4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGFR Aberrations: A Phase I Dose-Expansion Study. <i>Cancer Discovery</i> , 2022, 12, 402-415.	7.7	119
2	Efficacy and safety of cabozantinib for patients with advanced hepatocellular carcinoma based on albumin-bilirubin grade. <i>British Journal of Cancer</i> , 2022, 126, 569-575.	2.9	10
3	BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. <i>Journal of Hepatology</i> , 2022, 76, 681-693.	1.8	1,495
4	Outcomes Based on Plasma Biomarkers for the Phase 3 CELESTIAL Trial of Cabozantinib versus Placebo in Advanced Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2022, 11, 38-47.	4.2	20
5	Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA.. <i>Journal of Clinical Oncology</i> , 2022, 40, 379-379.	0.8	235
6	Validation and Characterization of FGFR2 Rearrangements in Cholangiocarcinoma with Comprehensive Genomic Profiling. <i>Journal of Molecular Diagnostics</i> , 2022, 24, 351-364.	1.2	5
7	Alpha-Fetoprotein as a Potential Surrogate Biomarker for Atezolizumab + Bevacizumab Treatment of Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2022, 28, 3537-3545.	3.2	52
8	Molecular pathogenesis and systemic therapies for hepatocellular carcinoma. <i>Nature Cancer</i> , 2022, 3, 386-401.	5.7	126
9	Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma. , 2022, 1, .		298
10	Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2022, 23, 995-1008.	5.1	237
11	Final results from ClariDH, a global, phase III, randomized, double-blind study of ivosidenib (IVO) versus placebo (PBO) in patients (pts) with previously treated cholangiocarcinoma (CCA) and an isocitrate dehydrogenase 1 (IDH1) mutation.. <i>Journal of Clinical Oncology</i> , 2021, 39, 266-266.	0.8	41
12	Abstract CT010: Primary results of phase 2 FOENIX-CCA2: The irreversible FGFR1-4 inhibitor futibatinib in intrahepatic cholangiocarcinoma (iCCA) with FGFR2 fusions/rearrangements. <i>Cancer Research</i> , 2021, 81, CT010-CT010.	0.4	28
13	Cabozantinib: An evolving therapy for hepatocellular carcinoma. <i>Cancer Treatment Reviews</i> , 2021, 98, 102221.	3.4	43
14	Hepatocellular Carcinoma – Origins and Outcomes. <i>New England Journal of Medicine</i> , 2021, 385, 280-282.	13.9	60
15	Phase II Trial of the Combination of Temezolimus and Sorafenib in Advanced Hepatocellular Carcinoma with Tumor Mutation Profiling. <i>Liver Cancer</i> , 2021, 10, 561-571.	4.2	11
16	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma. , 2021, 9, e002794.		43
17	Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 2991-3001.	0.8	257
18	Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 803-815.	3.7	205

#	ARTICLE	IF	CITATIONS
19	Final results from a phase II study of infigratinib (BGJ398), an FGFR-selective tyrosine kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma harboring an <i>FGFR2</i> gene fusion or rearrangement.. Journal of Clinical Oncology, 2021, 39, 265-265.	0.8	70
20	Hepatocellular carcinoma. Nature Reviews Disease Primers, 2021, 7, 6.	18.1	2,757
21	Harnessing big “omics” data and AI for drug discovery in hepatocellular carcinoma. Nature Reviews Gastroenterology and Hepatology, 2020, 17, 238-251.	8.2	90
22	Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline. Journal of Clinical Oncology, 2020, 38, 4317-4345.	0.8	350
23	Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial. ESMO Open, 2020, 5, e000714.	2.0	51
24	Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE158 and KEYNOTE028 studies. International Journal of Cancer, 2020, 147, 2190-2198.	2.3	288
25	Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma. Advances in Therapy, 2020, 37, 2678-2695.	1.3	37
26	Atezolizumab plus Bevacizumab – A Landmark in Liver Cancer. New England Journal of Medicine, 2020, 382, 1953-1955.	13.9	44
27	Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncology, The, 2020, 21, 796-807.	5.1	620
28	Phase Ib Study of Enzalutamide with or Without Sorafenib in Patients with Advanced Hepatocellular Carcinoma. Oncologist, 2020, 25, e1825-e1836.	1.9	13
29	Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma. Clinical Cancer Research, 2020, 26, 4795-4804.	3.2	58
30	Checkpoint Inhibitors for the Treatment of Advanced Hepatocellular Carcinoma. Clinical Liver Disease, 2020, 15, 53-58.	1.0	23
31	Immunotherapy in hepatocellular carcinoma: the complex interface between inflammation, fibrosis, and the immune response. , 2019, 7, 267.		156
32	Second-line chemotherapy in advanced biliary cancers: A retrospective, multicenter analysis of outcomes. Cancer, 2019, 125, 4426-4434.	2.0	49
33	Nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh class B cirrhosis: Safety and clinical outcomes in a retrospective case series. Cancer, 2019, 125, 3234-3241.	2.0	73
34	TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma. Cancer Discovery, 2019, 9, 1064-1079.	7.7	254
35	Hybrid Capture-Based Tumor Sequencing and Copy Number Analysis to Confirm Origin of Metachronous Metastases in <i>BRCA1</i> -Mutant Cholangiocarcinoma Harboring a Novel <i>YWHAZ-BRAF</i> Fusion. Oncologist, 2018, 23, 998-1003.	1.9	2
36	Cholangiocarcinoma – evolving concepts and therapeutic strategies. Nature Reviews Clinical Oncology, 2018, 15, 95-111.	12.5	1,051

#	ARTICLE	IF	CITATIONS
37	Cholangiocarcinoma With <i>FGFR</i> Genetic Aberrations: A Unique Clinical Phenotype. <i>JCO Precision Oncology</i> , 2018, 2, 1-12.	1.5	86
38	Phase II Study of BGJ398 in Patients With <i>FGFR</i> -Altered Advanced Cholangiocarcinoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 276-282.	0.8	524
39	Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. <i>New England Journal of Medicine</i> , 2018, 379, 54-63.	13.9	1,677
40	Overall Survival and Clinical Characteristics of BRCA-Associated Cholangiocarcinoma: A Multicenter Retrospective Study. <i>Oncologist</i> , 2017, 22, 804-810.	1.9	91
41	Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct <i>IDH</i> -Mutant Molecular Profiles. <i>Cell Reports</i> , 2017, 18, 2780-2794.	2.9	416
42	Phase I/II study of durvalumab and tremelimumab in patients with unresectable hepatocellular carcinoma (HCC): Phase I safety and efficacy analyses.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4073-4073.	0.8	133
43	ClariDH: A phase 3, multicenter, randomized, double-blind study of AG-120 vs placebo in patients with an advanced cholangiocarcinoma with an <i>IDH1</i> mutation.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS4142-TPS4142.	0.8	17
44	Circulating tumor cells in hepatocellular carcinoma: a pilot study of detection, enumeration, and next-generation sequencing in cases and controls. <i>BMC Cancer</i> , 2015, 15, 206.	1.1	103
45	Biliary Tract Cancers: Finding Better Ways to Lump and Split. <i>Journal of Clinical Oncology</i> , 2015, 33, 2588-2590.	0.8	14
46	Cases of Spontaneous Tumor Regression in Hepatobiliary Cancers: Implications for Immunotherapy?. <i>Journal of Gastrointestinal Cancer</i> , 2015, 46, 161-165.	0.6	13
47	Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas. <i>Cancer Discovery</i> , 2015, 5, 1040-1048.	7.7	226
48	Adjuvant sorafenib for liver cancer: wrong stage, wrong dose. <i>Lancet Oncology</i> , The, 2015, 16, 1279-1281.	5.1	19
49	Genomic Sequencing: Assessing The Health Care System, Policy, And Big-Data Implications. <i>Health Affairs</i> , 2014, 33, 1246-1253.	2.5	53
50	A case series of patients with <i>HER2</i> -overexpressed primary metastatic gastroesophageal adenocarcinoma. <i>Anticancer Research</i> , 2014, 34, 7357-60.	0.5	7
51	Novel Therapeutics in Hepatocellular Carcinoma: How Can We Make Progress?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, 33, e137-e142.	1.8	10
52	Predictive Biomarkers in Advance of a Companion Drug: Ahead of Their Time?. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 303-309.	2.3	7
53	Can we cure cholangiocarcinoma with neoadjuvant chemoradiation and liver transplantation? Time for a multicenter trial. <i>Liver Transplantation</i> , 2012, 18, 509-513.	1.3	5
54	Prognostic and Predictive Markers in Stage II Colon Cancer: Is There a Role for Gene Expression Profiling?. <i>Clinical Colorectal Cancer</i> , 2011, 10, 73-80.	1.0	72

#	ARTICLE	IF	CITATIONS
55	Personalized Medicine and Oncology Practice Guidelines: A Case Study of Contemporary Biomarkers in Colorectal Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011, 9, 13-25.	2.3	31
56	Drug development in advanced colorectal cancer: Challenges and opportunities. <i>Current Oncology Reports</i> , 2009, 11, 175-185.	1.8	4